Concentrating on elucidating cancer recurrence dynamics through a platform
originating from cancer stem cells in liquid biosamples, leveraging the CRISPR
Cas methodology. Concurrently, I am endeavoring to establish the 3R paradigm,
harmonizing in vivo and in vitro disease models at the epigenetic stratum.